These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 31272080)

  • 1. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors.
    Zhu X; Holmsen E; Park S; Willingham MC; Qi J; Cheng SY
    Oncotarget; 2018 Oct; 9(83):35408-35421. PubMed ID: 30459933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 signaling statuses determine the fate of resveratrol-treated anaplastic thyroid cancer cells.
    Wu J; Li YT; Tian XT; Liu YS; Wu ML; Li PN; Liu J
    Cancer Biomark; 2020; 27(4):461-469. PubMed ID: 31958078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma.
    Diaz D; Bergdorf K; Loberg MA; Phifer CJ; Xu GJ; Sheng Q; Chen SC; Byrant JM; Tigue ML; Hartmann H; Rohde SL; Netterville JL; Baregamian N; Goettel JA; Ye F; Lee E; Weiss VL
    Endocrine; 2024 Oct; 86(1):114-118. PubMed ID: 38806891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
    Wang Z; Qiu X; Zhang H; Li W
    J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
    De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
    Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
    Xiong L; Lin XM; Nie JH; Ye HS; Liu J
    Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Doolittle WKL; Zhao L; Cheng SY
    Thyroid; 2022 Aug; 32(8):937-948. PubMed ID: 35822558
    [No Abstract]   [Full Text] [Related]  

  • 12. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
    Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
    Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
    [No Abstract]   [Full Text] [Related]  

  • 14. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer.
    Jin Z; Cheng X; Feng H; Kuang J; Yang W; Peng C; Shen B; Qiu W
    Cell Physiol Biochem; 2017; 44(4):1471-1484. PubMed ID: 29190616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
    Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
    J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.